We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TEM's Collab for Oncology Patient Population Is Gaining Attention
Read MoreHide Full Article
Key Takeaways
Tempus AI partnered with NYU Langone Health to improve genetic diagnostics and data-driven cancer care.
TEM's collaboration covers biomarker discovery, AI tools and real-world data analysis to guide treatment.
TEM is expanding genomic testing access with Northwestern Medicine for early and advanced cancer patients.
Tempus AI (TEM - Free Report) recently started working with leading academic medical centers to broaden access to advanced genomic testing and data-driven cancer care. In line with this, Tempus and NYU Langone Health have formed a multi-year partnership to improve cancer care using advanced genetic testing and data analysis. The collaboration is aimed at improving genetic diagnostics, helping doctors make better treatment decisions and accelerating the development of new tests and data-driven tools.
Beyond its role in next-generation sequencing (NGS) testing, the partnership expands Tempus’ involvement to test validation, biomarker discovery, disease modeling, real-world data analysis, and AI-driven prediction tools. This will support the routine use of ongoing molecular profiling at the Perlmutter Cancer Center, allowing doctors to better understand each patient’s cancer, tailor targeted treatments and track how tumors respond to therapy or develop resistance.
In addition, Northwestern Medicine and Tempus are also collaborating to make genomic testing available to more cancer patients at Northwestern Medicine. The collaboration is aimed at providing nearly all cancer patients, including those diagnosed at an early stage, access to genetic testing.
This testing will help doctors better understand each patient’s cancer and choose more personalized and effective treatments. Tempus will support Northwestern Medicine by providing a wide range of genomic tests, including tissue testing, DNA and RNA profiling, liquid biopsy and minimal residual disease (MRD) testing.
Peer Update
An expanding NGS oncology portfolio is helping Illumina (ILMN - Free Report) drive the revolution in cancer genomics. In 2025, Illumina introduced TSO 500 v2, the next-generation version that offers built-in HRD biomarker detection and lower tissue sample input. In addition, Illumina is partnering with several global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TSO Comprehensive genomic profiling test, focusing on KRAS alterations, which are known to cause uncontrolled cell growth, leading to cancer.
Myriad Genetics (MYGN - Free Report) has identified several opportunities to grow its Oncology business, including expanding the diagnostic offerings, adding indications and genes to existing oncology tests, reducing friction for providers with automated ordering and reporting and investing in clinical evidence generation. This year, MYGN plans to introduce Precise Liquid, a liquid biopsy therapy selection test that can serve as a first-line offering or as a reflex test if the solid tumor is insufficient. Myriad Genetics is also developing Precise MRD, a monitoring test based on whole-genome sequencing, to deeply interrogate tumors, detect cancer recurrence earlier and help guide treatment decisions.
TEM’s Stock Price Performance
Over the past year, Tempus’ shares have rallied 114.3% compared with the industry’s 4.3% growth. The S&P 500 composite has improved 22% in the same time frame.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 7.84X compared with the industry average of 5.77X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate for 2025 has narrowed 1 cent to 64 cents.
Image: Bigstock
TEM's Collab for Oncology Patient Population Is Gaining Attention
Key Takeaways
Tempus AI (TEM - Free Report) recently started working with leading academic medical centers to broaden access to advanced genomic testing and data-driven cancer care. In line with this, Tempus and NYU Langone Health have formed a multi-year partnership to improve cancer care using advanced genetic testing and data analysis. The collaboration is aimed at improving genetic diagnostics, helping doctors make better treatment decisions and accelerating the development of new tests and data-driven tools.
Beyond its role in next-generation sequencing (NGS) testing, the partnership expands Tempus’ involvement to test validation, biomarker discovery, disease modeling, real-world data analysis, and AI-driven prediction tools. This will support the routine use of ongoing molecular profiling at the Perlmutter Cancer Center, allowing doctors to better understand each patient’s cancer, tailor targeted treatments and track how tumors respond to therapy or develop resistance.
In addition, Northwestern Medicine and Tempus are also collaborating to make genomic testing available to more cancer patients at Northwestern Medicine. The collaboration is aimed at providing nearly all cancer patients, including those diagnosed at an early stage, access to genetic testing.
This testing will help doctors better understand each patient’s cancer and choose more personalized and effective treatments. Tempus will support Northwestern Medicine by providing a wide range of genomic tests, including tissue testing, DNA and RNA profiling, liquid biopsy and minimal residual disease (MRD) testing.
Peer Update
An expanding NGS oncology portfolio is helping Illumina (ILMN - Free Report) drive the revolution in cancer genomics. In 2025, Illumina introduced TSO 500 v2, the next-generation version that offers built-in HRD biomarker detection and lower tissue sample input. In addition, Illumina is partnering with several global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TSO Comprehensive genomic profiling test, focusing on KRAS alterations, which are known to cause uncontrolled cell growth, leading to cancer.
Myriad Genetics (MYGN - Free Report) has identified several opportunities to grow its Oncology business, including expanding the diagnostic offerings, adding indications and genes to existing oncology tests, reducing friction for providers with automated ordering and reporting and investing in clinical evidence generation. This year, MYGN plans to introduce Precise Liquid, a liquid biopsy therapy selection test that can serve as a first-line offering or as a reflex test if the solid tumor is insufficient. Myriad Genetics is also developing Precise MRD, a monitoring test based on whole-genome sequencing, to deeply interrogate tumors, detect cancer recurrence earlier and help guide treatment decisions.
TEM’s Stock Price Performance
Over the past year, Tempus’ shares have rallied 114.3% compared with the industry’s 4.3% growth. The S&P 500 composite has improved 22% in the same time frame.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 7.84X compared with the industry average of 5.77X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate for 2025 has narrowed 1 cent to 64 cents.
Image Source: Zacks Investment Research
TEM currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.